281,700 Shares in GoodRx Holdings, Inc. (NASDAQ:GDRX) Purchased by Tocqueville Asset Management L.P.

Tocqueville Asset Management L.P. purchased a new stake in GoodRx Holdings, Inc. (NASDAQ:GDRX - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 281,700 shares of the company's stock, valued at approximately $1,310,000. Tocqueville Asset Management L.P. owned 0.07% of GoodRx at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of GDRX. Fortem Financial Group LLC purchased a new position in shares of GoodRx in the 3rd quarter worth $772,000. Barclays PLC raised its holdings in shares of GoodRx by 1,316.1% in the 3rd quarter. Barclays PLC now owns 140,113 shares of the company's stock worth $973,000 after purchasing an additional 130,219 shares during the period. Charles Schwab Investment Management Inc. lifted its stake in shares of GoodRx by 5.8% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 480,123 shares of the company's stock valued at $3,332,000 after purchasing an additional 26,262 shares in the last quarter. IMC Chicago LLC purchased a new stake in shares of GoodRx during the 4th quarter worth about $304,000. Finally, Pier Capital LLC acquired a new stake in GoodRx during the 3rd quarter worth approximately $3,259,000. Institutional investors and hedge funds own 63.77% of the company's stock.

GoodRx Price Performance

Shares of NASDAQ:GDRX remained flat at $4.64 during midday trading on Monday. 1,371,513 shares of the company were exchanged, compared to its average volume of 1,355,414. The stock has a market cap of $1.78 billion, a PE ratio of -154.67, a P/E/G ratio of 2.46 and a beta of 1.25. The company's 50 day simple moving average is $4.75 and its two-hundred day simple moving average is $5.39. The company has a debt-to-equity ratio of 0.70, a current ratio of 5.48 and a quick ratio of 5.48. GoodRx Holdings, Inc. has a fifty-two week low of $4.09 and a fifty-two week high of $9.26.

Remove Ads

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the stock. Wells Fargo & Company decreased their price objective on shares of GoodRx from $9.00 to $8.00 and set an "overweight" rating for the company in a research note on Friday, February 28th. Citigroup decreased their target price on GoodRx from $7.00 to $6.25 and set a "buy" rating for the company in a research report on Friday, January 10th. Mizuho initiated coverage on GoodRx in a report on Wednesday, December 4th. They set a "neutral" rating and a $5.00 target price on the stock. Morgan Stanley lowered their price objective on shares of GoodRx from $7.00 to $6.00 and set an "equal weight" rating for the company in a research report on Tuesday, December 17th. Finally, KeyCorp reduced their target price on shares of GoodRx from $7.00 to $6.00 and set an "overweight" rating on the stock in a research report on Wednesday, January 8th. Three equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $8.18.

GoodRx Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.